A Phase 3 interventional study of Olatorepatide and Placebo in Overweight or Obesity Without Diabetes, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity.
In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight or obese but do not have diabetes.
The study is looking at:
3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 78 across 3,127 interventional studies indexed under Overweight.
Browse Overweight studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Olatorepatide
Drug: Olatorepatide
Drug: Olatorepatide
Drug: Placebo
Drug: Placebo
Administered per the protocol
Also known as: HS-20094
Administered per the protocol
Percent change in body weight
Time frame: From baseline to week 72
Change in body weight
Time frame: From baseline to week 72
Occurrence of ≥5% reduction in body weight
Time frame: From baseline to week 72
Occurrence of ≥10% reduction in body weight
Time frame: From baseline to week 72
Occurrence of ≥15% reduction in body weight
Time frame: From baseline to week 72
Occurrence of ≥20% reduction in body weight
Time frame: From baseline to week 72
Change in waist circumference
Time frame: From baseline to week 72
Change in Systolic Blood Pressure (SBP)
Time frame: From baseline to week 72
Change in Diastolic Blood Pressure (DBP)
Time frame: From baseline to week 72
Change in Hemoglobin A1C (HbA1c)
Time frame: From baseline to week 72
Change in Fasting Plasma Glucose (FPG)
Time frame: From baseline to week 72
Percent change in total cholesterol
Time frame: From baseline to week 72
Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)
Time frame: From baseline to week 72
Percent change in High-Density Lipoprotein Cholesterol (HDL-C)
Time frame: From baseline to week 72
Percent change in non-HDL-C
Time frame: From baseline to week 72
Percent change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C)
Time frame: From baseline to week 72
Percent change in triglycerides
Time frame: From baseline to week 72
Percent change in Apolipoprotein B (ApoB)
Time frame: From baseline to week 72
Percent change in high-sensitivity C-Reactive Protein (hs-CRP)
Time frame: From baseline to week 72
Percent change in urine Albumin-Creatinine Ratio (uACR)
Time frame: From baseline to week 72
Change in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Physical Function score
The IWQOL-Lite-CT is a 20-item PRO measure designed to assess the impact of changes in weight on patients' physical and psychosocial functioning. The range of possible scores for the IWQOL-Lite-CT is 0 to 100. Higher values indicate better participant functioning.
Time frame: From baseline to week 72
Change in IWQOL-Lite-CT Physical Composite score
The IWQOL-Lite-CT is a 20-item PRO measure designed to assess the impact of changes in weight on patients' physical and psychosocial functioning. The range of possible scores for the IWQOL-Lite-CT is 0 to 100. Higher values indicate better participant functioning.
Time frame: From baseline to week 72
Change in IWQOL-Lite-CT Total score
The IWQOL-Lite-CT is a 20-item PRO measure designed to assess the impact of changes in weight on patients' physical and psychosocial functioning. The range of possible scores for the IWQOL-Lite-CT is 0 to 100. Higher values indicate better participant functioning.
Time frame: From baseline to week 72
Concentrations of olatorepatide in plasma
Time frame: Up to approximately 76 weeks
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
Time frame: Up to approximately 72 weeks
Magnitude of ADA to olatorepatide
Time frame: Up to approximately 72 weeks
Occurrence of Neutralizing Antibody (NAb) to olatorepatide
Time frame: Up to approximately 72 weeks
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to approximately 76 weeks
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.
Of 127 industry-sponsored phase 3 interventional studies under Overweight, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's planned 25 months is above that.
Counting every sponsor, half of 136 studies reached it within 21 months; a quarter within 17 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olatorepatide